SOMAÍ Pharmaceuticals

Home
Australia
Brisbane, QLD
SOMAÍ Pharmaceuticals

Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU.

A leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio Somai Pharmaceuticals LTD is a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoi

d-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Somai's product development knowledge was honed in the competitive American market, and is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Somai has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Somai stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Somai’s primary goal is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.

21/08/2026

SOMAÍ at Cannafair 2026! 🔵

From 21–23 August, our team is at Areal Böhler in Düsseldorf, connecting with partners, industry professionals, and the wider cannabis community at one of Germany’s major cannabis events.

As Germany continues to be an important market for SOMAÍ, we’re looking forward to discussing the latest developments in medical cannabis, innovative cannabinoid-based medicines, and the future of the industry.

Our Founder, Michael Sassano, will also be attending the event and available for meetings and discussions throughout Cannafair.

🔹 21–23 August 2026
🔹 Areal Böhler, Düsseldorf

Attending Cannafair? Come meet the SOMAÍ team!

14/08/2026

What does it really take for U.S.-grown cannabis flower to succeed in Europe?

In his latest article for Business of Cannabis, SOMAÍ Founder and Interim CEO Michael Sassano breaks down the economics behind exporting flower into Germany, the UK and Australia — and why attractive retail prices don’t necessarily translate into attractive margins for producers.

From importer and distributor margins to pharmacy and clinic costs, a significant share of the final retail price can remain within the channel. The key question is therefore not simply where cannabis sells for more — but how much of the value chain an operator controls.

Michael also explores why EU-GMP infrastructure, local distribution and vertical integration can fundamentally change the equation for companies looking at Europe as a long-term market rather than a short-term trading opportunity.

🔹 Read the full analysis in Business of Cannabis: https://businessofcannabis.com/selling-us-grown-flower-to-europe-what-the-margin-actually-says/

12/08/2026

☀️ Summer's in full swing, but at NovaSoma, SOMAÍ's cultivation facility, the work never slows down.

While the season calls for slower days, our team's hands stay busy - carefully hand-trimming every flower to preserve the quality patients rely on. Behind every bud is a process built on precision, care, and an unwavering commitment: patients come first, always.

No shortcuts. No pauses. Just consistent, quality medicine - cultivated with purpose at NovaSoma, SOMAÍ's home of cultivation. 🌿

31/07/2026

The reclassification of cannabis in the United States could have an impact far beyond its domestic market.

In his article for CannaReporter, Michael Sassano, Founder and Interim CEO of SOMAÍ, explores how this shift could accelerate medical research, cross-border investment and collaboration between US operators and established European pharmaceutical platforms.

As the global medical cannabis industry enters its next stage, regulated markets, EU-GMP standards and international distribution networks will play an increasingly important role in bringing cannabinoid-based medicines to patients worldwide.

🔹 Read the full article: https://cannareporter.eu/en/2026/07/06/US-cannabis-reclassification-boosts-global-medical-cannabis-market/

27/07/2026

🔹 Last month, we welcomed a group of Italian healthcare professionals to Portugal for a dedicated visit focused on scientific exchange, medical education, and the future of cannabinoid-based medicines.

The program included a tour of SOMAÍ Pharmaceuticals’ EU-GMP manufacturing facility and NovaSoma’s indoor cultivation site, offering an inside look at the processes, expertise, and standards behind our pharmaceutical extracts and medical cannabis flower.

Thank you to all the healthcare professionals who joined us and contributed to the discussions, and to our Italian partner, Materia Medica Processing, for making this visit possible. 💙

23/07/2026

🔹 WE ARE HIRING

SOMAÍ is growing, and we are looking for talented people to join our team.

Explore our current opportunities and discover how you can contribute to the future of cannabinoid-based medicines.

🌐 View open positions: somaipharma.eu/career/
📩 Send your CV to: [email protected]

Join us and become part of a global, innovative and fast-growing pharmaceutical company.

17/07/2026

🔵 The foundation of every SOMAÍ extract.

Purification is a critical step in creating the cannabinoid extract that forms the foundation of our entire extract portfolio.

By removing unwanted plant compounds while preserving the natural cannabinoid profile, we produce purified extracts designed for consistency, reliability, and pharmaceutical quality.

Built on advanced manufacturing. Backed by science.

14/07/2026

Europe is becoming the next major growth engine for the global medical cannabis industry. 🌐

In his article for IgniteIt, Michael Sassano explores why U.S. Multi-State Operators should look beyond state borders and consider Europe’s growing regulated markets.

From EU-GMP manufacturing to the Multi-Country Operator model, the article outlines what it takes to build a scalable global cannabis platform.

Read the full article: https://www.igniteit.com/news/europe-is-the-51st-state-for-msos-the-next-growth-engine-has-arrived/

08/07/2026

Our Business Support Manager, Judi McDonald, was proud to represent SOMAÍ Australia at the Medicinal Cannabis Reform Roundtable in Canberra, hosted by Cannabis Council Australia.

The roundtable brought together key voices from across the medicinal cannabis sector — including cultivators, manufacturers, prescribers, pharmacists, and patient advocates — for an important discussion on the future of reform in Australia.

The conversation focused on strengthening product quality, clinical governance, real-world evidence, and patient-centred access to regulated medicinal cannabis.

We’re proud to be part of these industry discussions as Australia continues to shape a stronger, safer, and more consistent framework for patients.

02/07/2026

Europe is no longer a secondary conversation in global cannabis.

In his latest byline for Krautinvest, Michael Sassano explores why 2026 is becoming a defining year for cannabis M&A, with global operators increasingly looking toward Europe and other regulated medical markets for their next phase of growth.

As countries including Germany, the UK, Australia, Poland, Switzerland, Italy, France, and Ireland continue to develop, the momentum is becoming clear: regulated medical cannabis markets are creating patient access, business opportunity, and stronger global infrastructure.

For SOMAÍ, this shift reinforces the importance of building a truly international platform — combining EU-GMP manufacturing, global distribution, and a broad portfolio of cannabinoid-based medicines designed for fast-growing medical markets.

Read Michael’s full article in krautinvest.de: https://krautinvest.de/european-cannabis-merger-mania-the-global-conversation-has-begun/

Address

Brisbane, QLD

Website

http://www.somaipharma.eu/

Alerts

Be the first to know and let us send you an email when SOMAÍ Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to SOMAÍ Pharmaceuticals:

Featured

Help for You - Rosemary Brown

Want your practice to be the top-listed Clinic in Brisbane?